Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Published version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Resistance invariably develops to antiandrogen therapies used to treat newly diagnosed prostate cancers, but effective treatments for castration-resistant disease remain elusive. Here, we report that the transcriptional coactivator CBP/p300 is required to maintain the growth of castration-resistant prostate cancer. To exploit this vulnerability, we developed a novel small-molecule inhibitor of the CBP/p300 bromodomain that blocks prostate cancer growth in vitro and in vivo. Molecular dissection of the consequences of drug treatment revealed a critical role for CBP/p300 in histone acetylation required for the transcriptional activity of the androgen receptor and its target gene expression. Our findings offer a preclinical proof of concept for small-molecule therapies to target the CBP/p300 bromodomain as a strategy to treat castration-resistant prostate cancer. Cancer Res; 77(20); 5564–75. ©2017 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies of a p300 inhibitor also reveal efficacy in patient-derived prostate tumor explants (Butler et al., 2019) and the growth of castration-resistant prostate cancer (Jin et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Jin et al., 2017
Citations
Cites
1 retracted
RETRACTED: A mathematical model explains saturating axon guidance responses to molecular gradients
Nguyen, H., Dayan, P., Pujic, Z., Cooper-White, J., & Goodhill, G. J. (2016) · eLife · doi:10.7554/elife.12248 · Cited by 1,221
RetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
nlme : Linear and nonlinear mixed effects models
DebRoy, S. (2006) · Medical Entomology and Zoology · Cited by 10,009
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
nlme: Linear and Nonlinear Mixed Effects Models
Pinheiro, J., R Core Team, & Bates, D. (1999) · CRAN: Contributed Packages · doi:10.32614/cran.package.nlme · Cited by 6,849
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“Prostate cancer cell growth is driven by activity of the androgen receptor (AR), and therapies that target the androgen signaling axis have been highly successful in treatment of the disease (1, 2).”
BackgroundIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Cited by
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Role of Androgen Receptor in Prostate Cancer: A Review
Fujita, K., & Nonomura, N. (2019) · The World Journal of Men's Health · doi:10.5534/wjmh.180040 · Cited by 483
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation
Raisner, R., Kharbanda, S., Jin, L., Jeng, E., Chan, E., Merchant, M., Haverty, P. M., Bainer, R., Cheung, T., Arnott, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.041 · Cited by 375
Self-citationTargeting the p300/CBP Axis in Lethal Prostate Cancer
Welti, J., Sharp, A., Brooks, N., Yuan, W., McNair, C., Chand, S. N., Pal, A., Figueiredo, I., Riisnaes, R., Gurel, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0751 · Cited by 275
Metadata
- Authors
- Jin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., Ly, J., Choo, E., Kaufman, S., Beresini, M. H., Romero, F. A., Magnuson, S., & Gascoigne, K. E.
- Affiliations
- Genentech (US)
- 2Department of Translational Oncology, Genentech, Inc., South San Francisco, California.
- Calico Life Sciences (US)
- 8Unity Biotechnology, Brisbane, California.
- Corresponding author
- Gascoigne, Karen E.
- ORCID
- Venue
- Cancer Research
- Published
- 2017-10-15
- Volume
- 77
- Issue
- 20
- Pages
- 5564-5575
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2745907548
- Cited by
- 153
- References
- 49
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 26 · 2023: 16 · 2022: 14 · 2021: 20 · 2020: 16 · 2019: 22 · 2018: 11 · 2017: 3
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, CBP/p300, bromodomain inhibition, small molecule inhibitors, histone acetylation, androgen receptor, transcriptional coactivator, antiandrogen resistance, prostate cancer treatment
- MeSH terms
- Protein Domains, Animals, Female, Humans, Male, Random Allocation, Receptors, Androgen, Transfection, Signal Transduction, Gene Expression, Mice, SCID, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Growth Processes, E1A-Associated p300 Protein, Mice, Small Molecule Libraries, Gene Knockdown Techniques, Molecular Targeted Therapy, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-0314
- The paper
- Jin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., Ly, J., Choo, E., Kaufman, S., Beresini, M. H., Romero, F. A., Magnuson, S., & Gascoigne, K. E. (2017). Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-0314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.